What Is a US Breast Bilateral Complete?

A “US Breast Bilateral Complete” is a complete diagnostic ultrasound examination of both breasts. You will typically see this phrase on a radiology order, an imaging report, or an insurance claim. The “US” stands for ultrasound, “bilateral” means both the left and right breast are scanned, and “complete” indicates the exam covers all four quadrants of each breast plus the area behind the nipple, rather than focusing on a single lump or region. This exam is commonly ordered as a supplement to mammography, especially for women with dense breast tissue, or when a doctor wants a thorough look at both breasts for screening or diagnostic reasons.

Why Both Breasts Get Scanned

You might wonder why both breasts need ultrasound if only one side has a concern. There are a few reasons. In screening situations, particularly for women with dense tissue, the goal is to find cancers that mammography might miss on either side. Breast tissue density can obscure tumors on a mammogram, and ultrasound can catch small, invasive cancers that are otherwise invisible. A systematic review found that supplemental ultrasound screening in women with dense breasts detected an additional roughly 4 cancers per 1,000 exams, with the vast majority being invasive tumors rather than slow-growing in-situ disease.¹ Scanning both sides ensures nothing is missed simply because attention was directed to the symptomatic breast.

In diagnostic situations, bilateral scanning helps establish a baseline and allows the radiologist to compare architecture between the two breasts. If one breast shows an unusual feature, checking the other side can reveal whether the same pattern appears symmetrically, which often means a normal variant, or asymmetrically, which may warrant closer evaluation. The comparison is itself diagnostic information.

What Happens During the Exam

The exam is performed by a sonographer or, in some settings, a radiologist. You lie on your back, sometimes slightly tilted to one side, and a small handheld transducer is moved across your skin using a layer of warm gel. Each breast is scanned methodically through all quadrants and the subareolar region (the tissue directly behind the nipple). The axillary areas, where lymph nodes sit near each armpit, are usually included as well. A study on axillary assessment in breast ultrasound confirmed that both ipsilateral and contralateral lymph nodes are routinely evaluated for shape, cortical features, and whether the fatty center of the node is preserved.²

A complete bilateral exam generally takes about 20 to 40 minutes, depending on breast size, tissue density, and whether the sonographer encounters anything that requires extra attention. It is painless, involves no radiation, and does not require any special preparation. You do not need to fast, stop medications, or avoid deodorant the way you might for a mammogram.

How It Differs From a Limited or Targeted Ultrasound

The word “complete” in the procedure name is not decorative. It distinguishes this exam from a “limited” or “targeted” breast ultrasound, which zeros in on one specific area, usually a palpable lump or an abnormality spotted on a mammogram. A limited exam might only scan one quadrant of one breast, while a complete bilateral exam systematically covers the full tissue volume of both breasts. Insurance billing codes distinguish between these: the complete exam has its own code because it involves substantially more scanning time and a broader diagnostic scope.

This distinction matters practically. If your doctor is concerned about a single lump you can feel, a targeted scan of that area might be all that is needed. But if the concern is screening for occult disease in dense tissue, or if there are symptoms on both sides, the complete bilateral version captures far more information. The choice between the two is a clinical decision made by your ordering physician based on the reason for the exam.

The Dense Breast Connection

Dense breast tissue is the single most common reason you will see a bilateral complete breast ultrasound ordered as a supplement to routine mammography. Breast density is rated on a four-point scale, and women in the two highest categories have tissue that appears mostly white on a mammogram, making it harder to spot tumors, which also appear white. Ultrasound does not share this limitation because it relies on sound waves rather than X-ray contrast.

The cancer-detection benefit of supplemental ultrasound varies by a woman’s overall risk. A large study from the Breast Cancer Surveillance Consortium found that ultrasound detected about 2 cancers per 1,000 exams overall in women with dense breasts, but the detection rate was much higher in women who also had an elevated risk of advanced cancer: roughly 5.5 per 1,000 exams in the high-risk group compared to about 1.3 per 1,000 in those at average risk.³ This finding has shaped how many radiologists and insurers think about the exam: it is most clearly beneficial when dense tissue and elevated risk overlap.

A separate large retrospective study of over 100,000 screening exams found that when mammography (using 3D tomosynthesis) was negative but ultrasound flagged something, ultrasound picked up an additional 1 cancer per 1,000 women screened.⁴ That is a modest number in absolute terms, but those are real cancers that would have gone undetected until the next screening cycle or until they became palpable.

The False-Positive Trade-Off

The catch with supplemental ultrasound is that it generates more false alarms. A finding that looks suspicious on ultrasound but turns out to be benign after further workup is called a false positive. For screening ultrasound in dense breasts, recall rates (the proportion of women called back for additional imaging or biopsy) have been reported at about 14%.¹ That means roughly one in seven women who undergoes a screening bilateral breast ultrasound will be called back, most of whom will turn out to be fine after additional evaluation.

The ASTOUND-2 trial, which compared supplemental ultrasound to supplemental tomosynthesis in women with dense breasts and negative mammograms, found that ultrasound detected more cancers but also caused more false-positive recalls than tomosynthesis did. The false-positive recall rate was about 1% for ultrasound versus 0.3% for tomosynthesis in that trial.⁵ This underscores a real trade-off: more cancers found also means more benign findings chased down with callbacks, additional imaging, and sometimes biopsies that turn out to be unnecessary.

For the individual woman, a false positive means anxiety, extra appointments, and possibly a needle biopsy that yields a benign result. These are not trivial. Whether the cancer-detection benefit outweighs the false-positive burden depends on your personal risk, and this is something worth discussing with your doctor rather than assuming one answer fits everyone.

Handheld Versus Automated Ultrasound

There are two main ways a complete bilateral breast ultrasound can be performed: handheld and automated. Handheld ultrasound (sometimes abbreviated HHUS) is the traditional approach. A trained sonographer moves a transducer across each breast in real time, adjusting angle and pressure as they go. The operator sees the images live and can linger on areas that look unusual.

Automated breast ultrasound (ABUS) uses a large transducer pad that covers a broader area of the breast at once. The device moves across the breast on its own, collecting a standardized 3D volume of images. The radiologist then reviews these volumes on a workstation, scrolling through slices much like reviewing a CT scan. One advantage of ABUS is standardization: the image set does not depend on the individual sonographer’s technique. A study comparing the two approaches found that ABUS had a higher specificity than handheld ultrasound, meaning it was better at correctly identifying non-cancerous findings as benign, while handheld ultrasound had higher sensitivity, meaning it was slightly better at catching actual cancers.⁶

Another study in women recalled after mammography screening found that handheld and automated ultrasound had identical sensitivity for detecting cancer among suspicious mammographic findings. The specificity was slightly higher for handheld ultrasound in that setting.⁷ In practical terms, both methods are effective. ABUS has the edge in reproducibility and may detect certain lesions that handheld ultrasound misses, though handheld scanning picks up some findings that ABUS does not. A study comparing the two methods found that while overall concordance between them was about 81%, ABUS detected additional high-risk lesions that the handheld exam missed, and handheld ultrasound found lesions that ABUS did not capture.⁸

Which method you receive depends largely on what your imaging center has available. Most facilities still use handheld ultrasound because ABUS requires specific equipment and training. If you have a choice, neither method is clearly superior overall. They have complementary strengths.

Understanding the Results

Your ultrasound results will be reported using the BI-RADS system, a standardized scale that runs from 0 to 6. This is the same framework used for mammography, so if you have seen mammogram results before, the categories will look familiar. The categories most relevant to a screening or diagnostic bilateral breast ultrasound are:

BI-RADS 1: Negative. Nothing abnormal was seen.
BI-RADS 2: Benign finding. Something was seen, like a simple cyst, but it is clearly not cancer.
BI-RADS 3: Probably benign. The finding has a very low chance of being cancer, and short-term follow-up imaging, usually at six months, is recommended rather than biopsy.
BI-RADS 4: Suspicious. Biopsy is recommended. This category has subcategories (4A, 4B, 4C) reflecting increasing levels of concern.
BI-RADS 5: Highly suggestive of malignancy. Biopsy is strongly recommended.
BI-RADS 0: Incomplete. Additional imaging is needed before a final assessment can be made.

A study assessing the diagnostic accuracy of BI-RADS classification on breast ultrasound found that overall accuracy was about 86%, with a sensitivity of about 91% and specificity of 80%.⁹ In plain terms, the system catches most cancers and correctly classifies most benign lesions, but it is not perfect in either direction.

What Happens With a BI-RADS 3 Finding

A BI-RADS 3 result is the one that generates the most confusion and anxiety. It means the radiologist sees something that is almost certainly benign but warrants a follow-up scan, usually six months later, to confirm it is not growing. The conventional malignancy rate for BI-RADS 3 lesions is very low, generally quoted at under 2%.

Research has looked at which features of BI-RADS 3 lesions might warrant earlier concern. One study found that lesions larger than about 12 mm on the long axis at baseline, or those growing beyond 16 mm on the long axis by the six-month follow-up, deserved closer scrutiny or biopsy. The study also noted that the pattern of blood flow within the lesion could help distinguish between BI-RADS 3 and the more suspicious BI-RADS 4 category.¹⁰

A large real-world study from Shenzhen spanning over five years of screening data found that for BI-RADS 3 lesions, imaging surveillance was preferable to rushing into biopsy. Among lesions that were biopsied, those biopsied more than a year after the initial finding had a higher cancer yield than those biopsied within the first three months, suggesting that the lesions that do turn out to be cancer tend to declare themselves over time through growth or changing features.¹¹ The takeaway is that if you receive a BI-RADS 3 result, your doctor’s recommendation to wait and recheck in six months is well supported by evidence, not a sign that your concern is being dismissed.

Complicated Cysts and Other Gray-Zone Findings

Breast ultrasound sometimes turns up findings that are not clearly solid and not clearly a simple fluid-filled cyst. These so-called complicated cysts contain internal echoes, which could be debris from old bleeding, thick fluid, or in rare cases, a small solid component. The radiologist evaluates whether the echogenic material inside moves when you change position and checks for blood flow using Doppler. If the material shifts freely and there is no blood-flow signal, it is almost certainly benign. If blood flow is detected within a solid-looking component on the cyst wall, further evaluation is needed. According to data from the ACRIN 6666 study, only about 12% of complicated cysts that were flagged on ultrasound turned out to be solid lesions on further workup, and the malignancy rate was less than half a percent.¹²

If you see something described as a “complicated cyst” on your report, it usually leads to a BI-RADS 3 classification with six-month follow-up, not an immediate biopsy. The distinction between complicated cysts and truly complex masses with solid components is one of the judgment calls that makes breast ultrasound interpretation an art as well as a science.

Insurance, Dense Breast Laws, and Access

Whether your insurance covers a bilateral complete breast ultrasound depends on where you live and why the exam was ordered. In the United States, dense breast notification laws now exist in all 50 states, requiring that women be told if their mammogram shows dense tissue. But notification alone does not guarantee insurance coverage for supplemental screening.

A 2026 study published in JAMA Network Open examined the impact of different state-level policies. States that only required notification of dense tissue saw a modest bump in ultrasound use, roughly 13 additional exams per 1,000 women screened. States that went further and mandated insurance coverage for supplemental screening saw a much larger effect: about 47 additional ultrasound exams per 1,000 women. Insurance coverage laws were also associated with nearly double the odds that a woman with dense breasts would receive supplemental ultrasound.¹³ The practical lesson: if you have dense breasts and want supplemental ultrasound, check whether your state mandates coverage. If it does not, you may need to advocate with your insurer or discuss out-of-pocket costs with your imaging center.

When the exam is ordered for a diagnostic reason, such as evaluating a lump or investigating an abnormal mammogram, insurance coverage is generally less of an issue because diagnostic imaging is treated differently from screening under most plans.

The Physical Demands on the Person Performing Your Exam

Here is something patients rarely think about: handheld breast ultrasound is physically grueling for the person performing it. The sonographer must hold a transducer in one hand, apply steady pressure, and maintain awkward arm and shoulder positions for the duration of the scan. A kinematic study assessing physician posture during breast and abdominal ultrasound found that breast ultrasound, particularly of the left breast, was associated with consistently medium-to-high musculoskeletal loading. Ergonomic scores indicated substantial strain that could increase the risk of repetitive-use injuries over a career.¹⁴

This is one of the practical arguments for automated breast ultrasound systems. ABUS reduces the physical burden on the operator because the device does the scanning mechanically. In clinics that perform high volumes of screening ultrasound, sonographer burnout and repetitive strain injuries are real operational concerns. If ABUS becomes more widely available, it could help sustain the workforce needed to offer supplemental screening to millions of women with dense tissue.

Artificial Intelligence and Where Breast Ultrasound Is Headed

AI is being actively developed for breast ultrasound, and the technology is moving fast. AI tools fall into two broad categories. Perception AI helps detect lesions that the human eye might miss, flagging areas in the image that warrant closer attention. Interpretation AI helps classify findings, distinguishing benign from suspicious lesions and potentially assigning BI-RADS categories. A systematic review found that dozens of studies have now tested one or both types, with some systems potentially reducing the need for a highly trained radiologist or sonographer to perform or interpret the exam.¹⁵ That possibility is particularly significant for clinics in resource-limited settings where specialist expertise is scarce.

For automated breast ultrasound in particular, AI models are being trained on 3D image volumes to detect lesions across multiple views. One model tested on multi-center datasets achieved a cancer detection rate above 90% at a low false-positive rate, matching the performance of experienced sonologists.¹⁶ These tools are not yet standard in clinical practice, but they represent a plausible future in which AI handles the initial read of your ultrasound and a human radiologist confirms or overrides the computer’s assessment. The combination could improve both speed and accuracy while reducing the burden on overstretched imaging departments.